{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:25:52Z","timestamp":1792193152903,"version":"4.4.0"},"reference-count":13,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Effisayil 1 was a multicentre, randomized, double\u2010blind, placebo\u2010controlled study of the anti\u2010interleukin (IL)\u201036 receptor monoclonal antibody, spesolimab, in patients presenting with a generalized pustular psoriasis (GPP) flare. Previously published data from this study revealed that within 1\u2009week, rapid pustular and skin clearance were observed in patients receiving spesolimab versus placebo. In this pre\u2010specified subgroup analysis, the efficacy of spesolimab was evaluated according to patient demographic and clinical characteristics at baseline in patients receiving spesolimab (<jats:italic>n<\/jats:italic>\u2009=\u200935) or placebo (<jats:italic>n<\/jats:italic>\u2009=\u200918) on Day 1. Efficacy was by assessed by achievement of primary endpoint (Generalized Pustular Psoriasis Physician Global Assessment [GPPGA] pustulation subscore of 0 at Week 1) and key secondary endpoint (GPPGA total score of 0 or 1 at Week 1). Safety was assessed at Week 1. Spesolimab was found to be efficacious and had a consistent and favourable safety profile in patients presenting with a GPP flare, regardless of patient demographics and clinical characteristics at baseline.<\/jats:p>","DOI":"10.1111\/exd.14824","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:53:09Z","timestamp":1683204789000},"page":"1279-1283","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre\u2010specified patient subgroups in the Effisayil 1 study"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7395-9931","authenticated-orcid":false,"given":"A. D.","family":"Burden","sequence":"first","affiliation":[{"name":"School of Infection and Immunity University of Glasgow  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Y.","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Affiliated Hospital Zhejiang University, School of Medicine  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"D.","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"P.","family":"van de Kerkhof","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hu","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim (China) Investment Co., Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Quaresma","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-2028","authenticated-orcid":false,"given":"C.","family":"Thoma","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7796-5746","authenticated-orcid":false,"given":"S. E.","family":"Choon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Sultanah Aminah, Clinical School Johor Bahru Monash University Malaysia  Subang Jaya Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14523"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14386"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3388"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16084"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00658-9"},{"key":"e_1_2_10_7_1","unstructured":"FDA U.Spesolimab Prescribing Information. FDA.2022. Accessed 28 October 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761244s000lbl.pdf. Published 2022."},{"key":"e_1_2_10_8_1","unstructured":"Boehringer\u2010Ingelheim.European Commission approves SPEVIGO\u00ae (spesolimab) for generalized pustular psoriasis flares.2022. Accessed 22 December 2022.https:\/\/www.boehringer\u2010ingelheim.com\/human\u2010health\/skin\u2010diseases\/gpp\/european\u2010commission\u2010approves\u2010spevigo\u2010spesolimab\u2010generalized. Published 2022."},{"key":"e_1_2_10_9_1","unstructured":"Boehringer\u2010Ingelheim.First\u2010ever treatment aimed at alleviating acute symptoms in pustular psoriasis (media release).2022. Accessed 22 December 2022.https:\/\/www.boehringer\u2010ingelheim.jp. Published 2022."},{"key":"e_1_2_10_10_1","unstructured":"Boehringer\u2010Ingelheim.The spesolimab injection approved for marketing. Accessed January 10 2023.https:\/\/www.ccfdie.org\/en\/gzdt\/webinfo\/2022\/12\/1668877790372263.htm. Published 2022."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043666"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.1999.01202.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2116003"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T09:53:00Z","timestamp":1702720380000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.14824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/exd.14824"],"URL":"https:\/\/doi.org\/10.1111\/exd.14824","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"2023-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}